Curemark To Present At BioPharm America™ 2010

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, will present at BioPharm America™ 2010, to be held September 15-17 in Boston at the Marriott Boston Copley Place, the company announced.


Dr. Joan Fallon, Curemark's founder and CEO, will provide an overview of the company's enzyme replacement therapy targeted to autism. Curemark is now in Phase III clinical trials for CM-AT, its autism treatment. She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the U.S. Food and Drug Administration (FDA) for the use of the company's compound CM-4612 to treat attention deficit hyperactivity disorder (ADHD). The FDA has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial to study the use of CM-4612 in the treatment of ADHD.


"We are very pleased to be able to give a presentation at this year's BioPharm America," Fallon said. "We welcome the opportunity to discuss our momentum with therapies that address neurological conditions for which there are currently no viable, physiologically-based treatments."


CM-AT, Curemark's autism treatment, targets enzyme deficiencies in autistic children that affect the availability of amino acids, the building blocks of chemicals essential for brain function. The company is currently conducting Phase III CM-AT trials at 13 sites nationwide with a planned total of 170 children. If approved, CM-AT, which has been granted Fast Track status from the FDA, will be one of the first therapies to address the underlying physiology of autism.


Organized by EBD Group, a leading partnering firm for the global life sciences industry, BioPharm America is intended as a forum where biotech and pharma executives from around the world can meet, and identify and enter strategic relationships. BioPharm America 2010 is the third annual international partnering conference.


Safe Harbor Statement


This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


Source: Curemark, LLC